| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1030009494 |
| P356 | DOI | 10.1245/S10434-006-9074-0 |
| P698 | PubMed publication ID | 17103075 |
| P50 | author | Leonard B. Saltz | Q37830465 |
| William R Jarnagin | Q40047643 | ||
| Yuman Fong | Q88653122 | ||
| Ronald P DeMatteo | Q89998373 | ||
| Peter Kornprat | Q90947692 | ||
| Nancy E Kemeny | Q114407269 | ||
| Leslie H. Blumgart | Q114407270 | ||
| Michael D'Angelica | Q122782494 | ||
| P2093 | author name string | Mithat Gonen | |
| Ki-Young Chung | |||
| P2860 | cites work | SU5416 delays wound healing through inhibition of TGF-beta 1 activation | Q44096699 |
| P433 | issue | 2 | |
| P921 | main subject | bevacizumab | Q413299 |
| hepatectomy | Q1514021 | ||
| P304 | page(s) | 759-765 | |
| P577 | publication date | 2006-11-11 | |
| P1433 | published in | Annals of Surgical Oncology | Q2853069 |
| P1476 | title | Lack of evidence for increased operative morbidity after hepatectomy with perioperative use of bevacizumab: a matched case-control study | |
| P478 | volume | 14 |
| Q48252313 | A phase II trial evaluating the feasibility of adding bevacizumab to standard osteosarcoma therapy. |
| Q39567268 | A reversal in the vascularity of metastatic liver tumors from colorectal cancer after the cessation of chemotherapy plus bevacizumab: contrast-enhanced ultrasonography and histological examination |
| Q33857704 | A single-institution experience with bevacizumab in the treatment of metastatic colorectal cancer and in conjunction with liver resection |
| Q37821285 | Advances in therapeutics for liver metastasis from colorectal cancer |
| Q82063645 | Bevacizumab and Ocular Wound Healing After Primary Pterygium Excision |
| Q57579592 | Bevacizumab et actes invasifs : recommandations pratiques |
| Q46183954 | Bevacizumab treatment before resection of colorectal liver metastases: safety, recovery of liver function, pathologic assessment |
| Q37821843 | Biologic modulation of chemotherapy in patients with hepatic colorectal metastases: the role of anti-VEGF and anti-EGFR antibodies |
| Q40086224 | Chemotherapy and its effect on liver hypertrophy: implications for portal vein embolization and resection |
| Q40069461 | Chemotherapy with bevacizumab does not affect liver regeneration after portal vein embolization in the treatment of colorectal liver metastases |
| Q43155564 | Chemotherapy's hepatotoxicity: what is the impact on surgery? |
| Q37732281 | Chemotherapy-associated hepatotoxicity: how concerned should we be? |
| Q37907117 | Chinese guidelines for the diagnosis and comprehensive treatment of hepatic metastasis of colorectal cancer |
| Q37428181 | Curable metastatic colorectal cancer: recommended paradigms |
| Q37436486 | Current management of colorectal hepatic metastasis |
| Q37125935 | Drug insight: antiangiogenic therapies for gastrointestinal cancers--focus on monoclonal antibodies |
| Q34254207 | Effect of bevacizumab added preoperatively to oxaliplatin on liver injury and complications after resection of colorectal liver metastases |
| Q38187905 | Effect of tyrosine kinase inhibitors on wound healing and tissue repair: implications for surgery in cancer patients |
| Q37821841 | Evolution of neoadjuvant therapy for extended hepatic metastases--have we reached our (non-resectable) limit? |
| Q37210172 | Evolving management of colorectal cancer |
| Q37774949 | Histological and immediate postoperative outcome after preoperative cetuximab: case-matched control study |
| Q37602292 | How to integrate biologicals in the continuum of care |
| Q35920259 | Impact of Bevacizumab on parenchymal damage and functional recovery of the liver in patients with colorectal liver metastases |
| Q51804140 | Impact of preoperative bevacizumab on complications after resection of colorectal liver metastases: case-matched control study. |
| Q44913424 | Impact of preoperative targeted therapy on postoperative complications after resection of colorectal liver metastases |
| Q36609383 | Incidence and predictive factors of clinically relevant bile leakage in the modern era of liver resections |
| Q37904901 | Liver resection for advanced or aggressive colorectal cancer metastases in the era of effective chemotherapy: a review |
| Q37406393 | Management of chemotherapy-associated hepatotoxicity in colorectal liver metastases |
| Q53480881 | Neoadjuvant Chemotherapy Followed by Maintenance Therapy With or Without Bevacizumab in Unresectable High-Grade Serous Ovarian Cancer: A Case-Control Study. |
| Q37969833 | Neoadjuvant and adjuvant therapy in relation to surgery for colorectal liver metastases |
| Q36299062 | Neoadjuvant bevacizumab persistently inactivates VEGF at the time of surgery despite preoperative cessation |
| Q37821842 | Neoadjuvant therapy of colorectal liver metastases: lessons learned from clinical trials. |
| Q37782046 | Optimizing resection for “responding” hepatic metastases after neoadjuvant chemotherapy |
| Q33622791 | Perioperative chemotherapy with bevacizumab and liver resection for colorectal cancer liver metastasis |
| Q45094736 | Perioperative complications after neoadjuvant chemotherapy with and without bevacizumab for colorectal liver metastases |
| Q42278220 | Practical questions in liver metastases of colorectal cancer: general principles of treatment |
| Q36615997 | Preoperative administration of bevacizumab is safe for patients with colorectal liver metastases |
| Q51193100 | Preoperative bevacizumab and surgery for colorectal liver metastases: a propensity score analysis. |
| Q85411312 | Preoperative treatment with bevacizumab in combination with chemotherapy in patients with unresectable metastatic colorectal carcinoma |
| Q46187152 | Recurrent disease four years after surgery and adjuvant chemotherapy. |
| Q33637887 | Safety of endoscopy in cancer patients on antiangiogenic agents: A retrospective multicenter outcomes study |
| Q35854745 | Sinusoidal obstruction syndrome (SOS) related to chemotherapy for colorectal liver metastases: factors predictive of severe SOS lesions and protective effect of bevacizumab. |
| Q42429760 | Surgical options for initially unresectable colorectal liver metastases |
| Q36934787 | Targeted therapies for kidney cancer in urologic practice |
| Q37797762 | The Timing of Chemotherapy and Surgery for the Treatment of Colorectal Liver Metastases |
| Q37784765 | The effects of bevacizumab on postoperative complications in patients undergoing colorectal and pancreatic cancer resection |
| Q37389557 | The role of cytoreductive nephrectomy in the era of molecular targeted therapy |
| Q37406167 | Timing of administration of bevacizumab chemotherapy affects wound healing after chest wall port placement. |
| Q36915973 | Tyrosine kinase inhibitors and anti-angiogenic therapies in kidney cancer |
| Q37695468 | Vascular endothelial growth factor targeted therapy in the perioperative setting: implications for patient care |
| Q84090284 | [Key events from the 4th French-speaking congress on digestive and hepatobiliary surgery: synthesis of the oral communications and report of symposium. December 4-6 2008, Paris] |
| Q82978669 | [The safety of perioperative bevacizumab use] |
Search more.